AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$ARTV

Aslan Fred sold $169K of ARTV

Aslan Fred (Chief Executive Officer) sold 23,463 shares of Artiva Biotherapeutics, Inc. (ARTV) at $7.20 ($0.17M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Aslan Fred
Published Oct 7, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The transaction is a primary disclosure but trivial in scale, offering limited trading insight.

02

Market read

Small insider sale with minimal market impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, reducing the informational content of the transaction.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filings disclose insider transactions; this filing reports a modest CEO share sale under a pre‑arranged plan.

Company-level read

Ticker impact

$ARTVBearishHigh confidence
Context

CEO Aslan Fred sold 23,463 shares for $168,880 via a 10b5‑1 plan, reducing his stake to 1.52 million shares.

Expected impact

likely modest pressure as the market prices in the CEO's share reduction

Evidence & confidence

A 10b5‑1 sale by the chief executive signals personal liquidity needs; the amount ($169K) is small relative to market cap, so impact is limited but negative.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale may be routine and not reflect any negative outlook; investors could view it as a neutral liquidity event.

Key entities

  • Company
    Artiva Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ARTV.

  • Person
    Aslan Fred

    Chief Executive Officer of Artiva Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min